← Axsome Therapeutics overview

Axsome Therapeutics vs Jazz Pharmaceuticals: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Axsome Therapeutics Inc (AXSM)

Q3 2026
▲4

Axsome's Alzheimer's Launch Drives Record Prescriptions, Pipeline Advances

  • Record Auvelity Prescriptions on Alzheimer's Launch Auvelity prescriptions hit a record ~23,500 weekly, with new-to-brand scripts reaching 3,800 as the Alzheimer's agitation launch grows. Patients 65+ now make up 31% of new scripts, up from 19%, showing strong demand and supporting the $8 billion peak-sales outlook.

    This is the core demand driver behind the stock's recent move and the biggest new commercial catalyst.

  • Pipeline Advances with AXS-12 PDUFA and Phase III Start AXS-12 for cataplexy got a May 1, 2027 PDUFA date, and Axsome dosed the first patient in a Phase III study of AXS-05 for smoking cessation. Management targets roughly one new drug filing per year through 2030, expanding the pipeline beyond current products.

    Shows new growth opportunities beyond Auvelity, which supports the long-term investment case.

  • Strong Q2 Revenue and Path to Cash Flow Positive Q2 net product revenue rose 46% to $218 million, led by Auvelity and Sunosi. Management expects revenue to grow faster than expenses, with $320 million cash funding operations into cash flow positivity, reducing financing risk.

    Financial strength and profitability path are key to sustaining investor confidence.

  • Analyst Backing and New Clinical Data B. Riley named Axsome a top biotech pick with a $300 price target ahead of Q3 earnings. New clinical data in depression and Alzheimer's agitation were presented, adding detail to the pipeline and supporting future regulatory interactions.

    Analyst endorsement and data reinforce the growth narrative and can attract investors.

September 2026
▲4

Axsome's Alzheimer's Launch Drives Record Prescriptions, Pipeline Advances

  • Record Auvelity Prescriptions on Alzheimer's Launch Auvelity prescriptions hit a record ~23,500 weekly, with new-to-brand scripts reaching 3,800 as the Alzheimer's agitation launch grows. Patients 65+ now make up 31% of new scripts, up from 19%, showing strong demand and supporting the $8 billion peak-sales outlook.

    This is the core demand driver behind the stock's recent move and the biggest new commercial catalyst.

  • Pipeline Advances with AXS-12 PDUFA and Phase III Start AXS-12 for cataplexy got a May 1, 2027 PDUFA date, and Axsome dosed the first patient in a Phase III study of AXS-05 for smoking cessation. Management targets roughly one new drug filing per year through 2030, expanding the pipeline beyond current products.

    Shows new growth opportunities beyond Auvelity, which supports the long-term investment case.

  • Strong Q2 Revenue and Path to Cash Flow Positive Q2 net product revenue rose 46% to $218 million, led by Auvelity and Sunosi. Management expects revenue to grow faster than expenses, with $320 million cash funding operations into cash flow positivity, reducing financing risk.

    Financial strength and profitability path are key to sustaining investor confidence.

  • Analyst Backing and New Clinical Data B. Riley named Axsome a top biotech pick with a $300 price target ahead of Q3 earnings. New clinical data in depression and Alzheimer's agitation were presented, adding detail to the pipeline and supporting future regulatory interactions.

    Analyst endorsement and data reinforce the growth narrative and can attract investors.

Latest
▲4

Axsome's Alzheimer's Launch Drives Record Prescriptions, Pipeline Advances

  • Record Auvelity Prescriptions on Alzheimer's Launch Auvelity prescriptions hit a record ~23,500 weekly, with new-to-brand scripts reaching 3,800 as the Alzheimer's agitation launch grows. Patients 65+ now make up 31% of new scripts, up from 19%, showing strong demand and supporting the $8 billion peak-sales outlook.

    This is the core demand driver behind the stock's recent move and the biggest new commercial catalyst.

  • Pipeline Advances with AXS-12 PDUFA and Phase III Start AXS-12 for cataplexy got a May 1, 2027 PDUFA date, and Axsome dosed the first patient in a Phase III study of AXS-05 for smoking cessation. Management targets roughly one new drug filing per year through 2030, expanding the pipeline beyond current products.

    Shows new growth opportunities beyond Auvelity, which supports the long-term investment case.

  • Strong Q2 Revenue and Path to Cash Flow Positive Q2 net product revenue rose 46% to $218 million, led by Auvelity and Sunosi. Management expects revenue to grow faster than expenses, with $320 million cash funding operations into cash flow positivity, reducing financing risk.

    Financial strength and profitability path are key to sustaining investor confidence.

  • Analyst Backing and New Clinical Data B. Riley named Axsome a top biotech pick with a $300 price target ahead of Q3 earnings. New clinical data in depression and Alzheimer's agitation were presented, adding detail to the pipeline and supporting future regulatory interactions.

    Analyst endorsement and data reinforce the growth narrative and can attract investors.

Jazz Pharmaceuticals PLC (JAZZ)

Q3 2026
▲2▼1

Jazz beats Q2, expands pipeline, but debt and competition weigh

  • Q2 beat and raised guidance Jazz beat Q2 estimates with $1.21B revenue (up 15.5%) and raised full-year guidance to $4.68B, signaling strong core business momentum.

    This is a key positive financial result that drove investor confidence.

  • Pipeline expansion via acquisitions Jazz acquired Actio Biosciences for $820M upfront and signed an AbCellera oncology collaboration, expanding its pipeline and future growth prospects.

    These strategic moves show Jazz's commitment to building its pipeline, a positive for long-term growth.

  • Zepzelca trial failure and competitive threat Zepzelca failed a Phase 3 second-line lung cancer trial, and a new Amgen/AstraZeneca combo threatens its position, though Ziihera's positive data and FDA label expansion provided a boost.

    This captures both the negative trial failure and the positive Ziihera news, plus the competitive threat.

  • Debt offering raises leverage concerns A larger-than-expected $1.1B exchangeable debt offering raised leverage and dilution concerns, pressuring shares despite pipeline momentum.

    This is a key negative factor that weighed on the stock during the period.

August 2026
▲2▼2

Jazz's cancer drug wins lift outlook as debt and rivals weigh

  • Ziihera survival data and FDA label expansion Jazz's gastric cancer drug Ziihera beat standard trastuzumab on overall survival in a large Phase 3 trial, and the FDA expanded its label on August 25. This opens a much bigger market and supports the stock's 47.5% year-to-date gain.

    This is the biggest new positive force for JAZZ, directly expanding its cancer franchise.

  • Upsized $1.1B debt offering pressures shares Jazz priced a larger-than-expected $1.1 billion exchangeable debt sale at low interest, but the stock fell 4% on the news. The move adds leverage and potential future share dilution, which investors dislike.

    This is a new capital-markets event that directly pushed JAZZ shares down.

  • New lung cancer rival threatens Zepzelca Amgen and AstraZeneca's Imfinzi-Imdelltra combo met its survival goal in first-line small-cell lung cancer maintenance. If approved, it would compete with Jazz's Zepzelca-Tecentriq combo, which was approved in October 2025, potentially limiting Zepzelca's sales.

    This is a fresh competitive threat to a key Jazz growth driver.

  • Zanidatamab FDA decision could bring milestone cash The FDA was set to decide on zanidatamab, co-developed with Zymeworks, by August 25. Approval would trigger a $250 million milestone payment to Jazz, with more possible from other markets, boosting near-term cash flow.

    This is a new regulatory catalyst with a direct financial benefit to JAZZ.

Latest
▲2▼2

Jazz's cancer drug wins lift outlook as debt and rivals weigh

  • Ziihera survival data and FDA label expansion Jazz's gastric cancer drug Ziihera beat standard trastuzumab on overall survival in a large Phase 3 trial, and the FDA expanded its label on August 25. This opens a much bigger market and supports the stock's 47.5% year-to-date gain.

    This is the biggest new positive force for JAZZ, directly expanding its cancer franchise.

  • Upsized $1.1B debt offering pressures shares Jazz priced a larger-than-expected $1.1 billion exchangeable debt sale at low interest, but the stock fell 4% on the news. The move adds leverage and potential future share dilution, which investors dislike.

    This is a new capital-markets event that directly pushed JAZZ shares down.

  • New lung cancer rival threatens Zepzelca Amgen and AstraZeneca's Imfinzi-Imdelltra combo met its survival goal in first-line small-cell lung cancer maintenance. If approved, it would compete with Jazz's Zepzelca-Tecentriq combo, which was approved in October 2025, potentially limiting Zepzelca's sales.

    This is a fresh competitive threat to a key Jazz growth driver.

  • Zanidatamab FDA decision could bring milestone cash The FDA was set to decide on zanidatamab, co-developed with Zymeworks, by August 25. Approval would trigger a $250 million milestone payment to Jazz, with more possible from other markets, boosting near-term cash flow.

    This is a new regulatory catalyst with a direct financial benefit to JAZZ.

July 2026
▲3▼1

Jazz beats Q2, raises guidance, and buys Actio Biosciences

  • Q2 revenue beat and raised full-year guidance Jazz reported Q2 revenue of $1.21 billion, beating estimates and up 15.5% from a year ago. Management raised full-year revenue guidance to $4.68 billion, well above Wall Street's expectation. Adjusted earnings per share missed, but the strong sales outlook and improved operating margin pushed shares up 2.5%.

    This is the biggest new event, directly showing stronger sales and a brighter outlook that lifts the stock.

  • Acquisition of Actio Biosciences for $820 million upfront Jazz agreed to buy privately held Actio Biosciences for $820 million upfront plus up to $500 million in milestones. This adds new rare-disease drug programs to Jazz's pipeline. Investors often see bolt-on deals as a sign of confidence and future growth, which supports the stock price.

    This is a fresh, concrete move that expands Jazz's pipeline and signals growth, directly affecting the investment case.

  • AbCellera cancer antibody collaboration Jazz signed a deal with AbCellera to discover new cancer antibodies for gastrointestinal and other solid tumors. Jazz paid $56 million upfront and could pay up to $792 million in milestones. This expands Jazz's oncology pipeline, a positive for long-term growth, though any revenue is years away.

    It is a new partnership that broadens Jazz's cancer research, supporting the stock's long-term potential.

  • Zepzelca fails second-line lung cancer trial Jazz's drug Zepzelca failed a phase 3 trial in second-line small-cell lung cancer, missing the main goal of helping patients live longer. However, Jazz's focus has already shifted to Zepzelca's first-line use, which is approved and growing fast. The failure is a setback but not a major financial blow.

    This is a new negative event, but its limited impact due to the first-line shift makes it a balanced point.

▲3▼1

Jazz beats Q2, raises guidance, and buys Actio Biosciences

  • Q2 revenue beat and raised full-year guidance Jazz reported Q2 revenue of $1.21 billion, beating estimates and up 15.5% from a year ago. Management raised full-year revenue guidance to $4.68 billion, well above Wall Street's expectation. Adjusted earnings per share missed, but the strong sales outlook and improved operating margin pushed shares up 2.5%.

    This is the biggest new event, directly showing stronger sales and a brighter outlook that lifts the stock.

  • Acquisition of Actio Biosciences for $820 million upfront Jazz agreed to buy privately held Actio Biosciences for $820 million upfront plus up to $500 million in milestones. This adds new rare-disease drug programs to Jazz's pipeline. Investors often see bolt-on deals as a sign of confidence and future growth, which supports the stock price.

    This is a fresh, concrete move that expands Jazz's pipeline and signals growth, directly affecting the investment case.

  • AbCellera cancer antibody collaboration Jazz signed a deal with AbCellera to discover new cancer antibodies for gastrointestinal and other solid tumors. Jazz paid $56 million upfront and could pay up to $792 million in milestones. This expands Jazz's oncology pipeline, a positive for long-term growth, though any revenue is years away.

    It is a new partnership that broadens Jazz's cancer research, supporting the stock's long-term potential.

  • Zepzelca fails second-line lung cancer trial Jazz's drug Zepzelca failed a phase 3 trial in second-line small-cell lung cancer, missing the main goal of helping patients live longer. However, Jazz's focus has already shifted to Zepzelca's first-line use, which is approved and growing fast. The failure is a setback but not a major financial blow.

    This is a new negative event, but its limited impact due to the first-line shift makes it a balanced point.